Capital Raise Strengthens HeartBeam’s Commercialization Strategy HeartBeam completed an $11.5 million public offering, including an over-allotment option. This funding supports R&D, regulatory, and commercialization activities, providing a runway for its innovative ECG technology. Strong institutional demand for shares signals investor confidence, though competition and FDA timelines remain hurdles.67